Loading...
Market
CDC recommends mRNA-1083 for adults 50+ by March 2025?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
CDC official recommendations or guidelines
Story
Moderna's mRNA-1083 Combo COVID-19 and Flu Vaccine Shows Stronger Immune Response in Phase 3 Trials
Jun 10, 2024, 11:10 AM
Moderna announced that its combination vaccine for COVID-19 and influenza generated a stronger immune response compared to separate shots against the two viruses. The investigational vaccine, mRNA-1083, showed positive results in a Phase 3 late-stage clinical trial, particularly in adults aged 50 and over. The Phase 3 data indicated that the combined vaccine is more effective than existing individual shots for both COVID-19 and flu. The company highlighted that the new vaccine could simplify immunization efforts by reducing the number of shots needed.
View original story
Similar markets
50 and older • 33%
30-49 • 33%
Under 30 • 33%
Yes • 50%
No • 50%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
FDA (USA) • 25%
EMA (Europe) • 25%
MHRA (UK) • 25%
TGA (Australia) • 25%
